Manisha Balwani
Clinical Genetics (M.D.) · New York, NYNPI 1548362759
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $127,158 of the $188,435 with a category attached, or 67.5%. 11 manufacturers reported payments, led by Sanofi at 47.2% of the total. Among clinical genetics (m.d.) clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $1185.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$89K
- Alnylam Pharmaceuticals Inc.$52K
- Recordati_rare_diseases_inc.$19K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- AstraZeneca$11K
- Bioverativ Therapeutics Inc.$2K
- plus $3K from 5 others
Across 285 payments — averaging $7201.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$742K
- Mitsubishi Tanabe Pharma Development America, Inc.$712K
- Tanabe Pharma America, Inc.$371K
- Sanofi US Services Inc.$219K
- Sanofi$9K
What the payments were for
- Consulting fees$127,15867%
- Speaking & faculty fees$19,03710%
- Travel & lodging$38,78821%
- Food & beverage$3,4522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 72 | $89,005 |
| Alnylam Pharmaceuticals Inc. | 54 | $51,711 |
| Recordati_rare_diseases_inc. | 6 | $18,841 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $12,735 |
| AstraZeneca | 8 | $11,300 |
| Bioverativ Therapeutics Inc. | 2 | $2,272 |
| Tanabe Pharma America, Inc. | 1 | $2,100 |
| Mirum Pharmaceuticals, Inc. | 1 | $142 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 1 | $115 |
| Biomarin Pharmaceutical Inc. | 3 | $115 |
| EUSA Pharma (US) LLC | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CERDELGA$33,050
- GIVLAARI$20,433
- GIVLARRI$15,106
- PANHEMATIN$14,943
- Kanuma$11,300
- CEREZYME$4,986
- XENPOZYME$3,673
- VPRIV$1,680
- AMVUTTRA$511
- Livmarli$142
- (810) Chenodal$142
- (820) Cholbam$142
- Carbaglu$124
How this compares
$188,435 in reported general payments places this provider in the 95th percentile of 49 clinical genetics (m.d.) providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VprivVelaglucerase Alfa | 12 | $408,088 |
Paid to pharmacies, not to this prescriber.
Other clinical genetics (m.d.) in New York
- Robert DesnickNew York$207K
- Jaya GaneshNew York$65K
- George DiazNew York$44K
- Christopher CunniffNew York$25K
- David BeckNew York$21K
- Kimihiko OishiNew York$15K
- Mary LopiccoloNew York$13K
- Noura Abul HusnNew York$6K
- Ronald WapnerNew York$5K
- Laura PisaniNew York$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.